Skip to content
April 16, 2024

Equity.Guru

Investment information for the new generation

Search

Tetra Biopharma

Closing the Diabetic Loop Before we get into this week’s sector roundup, let’s talk about diabetes. I am a sucker for sweets, so much so that I was diagnosed…
Not So Constipated Market I owe Flinstones Gummies my life. That’s a bit of an exaggeration, however, there’s no denying I cared more for my health as a kid…
Tetra Bio-Pharma (TBP.T) (“Tetra”) is a biopharmaceutical company focused on cannabinoid-derived drug discovery and development. The Company has an FDA and Health Canada cleared clinical program intended to bring…
Tetra Bio-Pharma (TBP.T) has announced the start of the REBORN1© clinical trial, designed to evaluate the effect of QIXLEEF™, the Company’s inhaled proprietary drug formulation. During this study, QIXLEEF™…
Tetra Bio-Pharma (TBP.T), a leader in cannabinoid-derived drug discovery and development, has announced that is has signed a Definitive Agreement with DanCann Pharma for the exclusive distribution of Reduvo™…
Tetra Bio-Pharma (TBP.T), a leader in cannabinoid-derived drug discovery and development, announced today that it has been granted a Health Canada Drug Establishment License (DEL) to distribute REDUVO soft…
Tetra Bio-Pharma (TBP.T) has shipped Qixleef, its investigational new drug, to the United States for initiation of the REBORN1 study. The REBORN1 study will investigate cannabis as an alternative…
It’s time for your Tuesday cannabis rundown. First up: The Green Organic Dutchman Holdings (TGOD.T) signed a letter of intent with the Societe quebecoise du cannabis (SQDC) before its…
Tetra Biopharma (TBP.V) has been busy conducting clinical development programs of two potential products, the first being Quixleef and the second Plenitude. Both involve dealing with uncontrolled pain in…